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DOI: 10.1039/c1jm11370dAmine and carboxylic acid-bifunctionalized iron oxide nanoparticles with robust silane linkages to the
nanoparticle surface were prepared with a versatile direct grafting protocol. The contrast in chemistry
of these two groups was highlighted by attaching a fluorophore, Rhodamine B isothiocyanate (RITC)
onto the amine group and an antibody (EPCAM – epithelial cell adhesion molecule) onto the
carboxylic acid groups. The iron oxide core and the RITC tags provide the MRI-fluorescent bi-modal
imaging capability. The EPCAM antibody is specific to a protein ubiquitously expressed on the
epithelial cell surface. These bifunctionalized nanoparticles target and then undergo facilitated uptake
into pancreatic cancer cells (Panc-1) in a time course-monitored controlled study. The integrated
optical imaging properties of these magnetic nanoparticles were utilized to monitor the interaction of
the nanoparticles with the EPCAM receptors on the cell membrane of the Panc-1 cells. The time-course
of the uptake for the targeted and the control particles by the cells was followed allowing the
localization within the cell and the impact of particle functionalization to be identified. This system is
a candidate for further development as a multi-modular imaging, diagnostic and delivery tool.Introduction
Pancreatic cancer is a major cause of cancer-related deaths in
both the US and Europe.1,2 Surgery with follow on chemo-
therapy offers the best chance of survival. However, due to late
presentation and diagnosis, this option is not possible for the
majority of patients. In order to improve the survival rate of
pancreatic cancer, adaptive novel diagnostic techniques are
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12650 | J. Mater. Chem., 2011, 21, 12650–12659a myriad of novel nanomaterials of various physical and chem-
ical properties available for scientists as diagnostic and thera-
peutic research tools including drug delivery agents, molecular
recognition agents, gene delivery agents, cancer treatment
materials and imaging contrast agents.3–11 Magnetic nano-
particles (MNPs) are of particular interest for nanomedicine as
they can be localized to the target tissue via a magnetic field.12,13
Crucially, however, this is unlikely in itself to achieve greater
tissue delivery of cargo, rather than just an accumulation around
the site. Thus, if such MNPs are additionally functionalized with
specific targeting ligands14–16 then they have the potential
advantage of greater delivery accuracy and facilitated uptake
into the site in question. In terms of a chemotherapeutic cargo,
this would reduce ‘off target’ side effects of the drugs on healthy
neighboring tissues, which are responsible for a number of
unpleasant and serious side effects. Similarly, the ability to image
a pathophysiological process at the cellular and molecular level
using Magnetic Resonance Imaging (MRI)17,18 or allied tech-
niques is currently impaired by the lack of specifically targeted
contrast agents. MNPs have been widely used as MRI contrast
enhancers19–21 due to their inherent ability to shorten T2 relaxa-
tion time of the surrounding tissue protons. The drawbacks of
the existing MRI contrast agents is their application in the
detection of liver or spleen tumours which is based on the uptake
of the MNPs by the cells of the mononuclear phagocyte system
(passive targeting).22,23 Development of specific contrast agents
for all imaging modalities (MRI, Computerized TomographyThis journal is ª The Royal Society of Chemistry 2011
Fig. 1 Iron oxide MNPs functionalization. (a) APTES, toluene, 110 C,
overnight to produce amine functionalized nanoparticles denoted as
Fe3O4-NH2; (b) succinic anhydride, dimethylformamide, room temper-
ature, 24 h to produce bifunctionalized nanoparticles denoted as Fe3O4-
NH2/COOH; (c) RITC, sodium bicarbonate buffer, room temperature,
overnight to produce fluorescently labelled nanoparticles denoted as
Fe3O4-NH-RITC/COOH.
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View Online(CT) and Positron Emission Tomography (PET)) targeted to
tissue/tumours would be central in resolving diagnostic
dilemmas.
The key element for the attachment of desired targeting
molecules onto MNPs lies on the surface modification with
suitable organic functionalities. This can be achieved via: poly-
mer coating,24 surfactant adsorption12 and direct grafting of
organo-silanes.25 A number of synthetic polymers such as PEG-
poly(ethylene glycol),26 poly(acrylamide)27 and PVA-poly(vinyl
alcohol)28 as well as naturally occurring polymers such as
dextran29 and chitosan30 have been used to modify the surface
properties of the MNPs for enhancing their colloidal stability,
biocompatibility and low protein interaction. However, these
polymers physisorbed onto the surface of nanoparticles by
electrostatic attraction or hydrogen-bonding have shown limited
stability because the polymer is likely to detach from the
magnetic core under the physiological environment in time.31
Additionally, modification using polymers reduces the overall
magnetic response of MNPs due to the decrease in total iron
content.32 An alternative route to modify the surface of MNPs is
to use small molecules such as functional silanes. The direct
silanization of the surface of MNPs forms a robust, covalent
coating with grafted functional groups on the surface. This
allows further functionalization on the primary functional
groups to generate a wide variety of surface functionalities to suit
specific applications.33–35 3-Aminopropyltriethoxysilane
(APTES) is commonly used to prepare cationic amine groups on
MNPs.36 This system offers only one functional group for
chemical conjugation with targeting ligands or fluorescent tags.
However, if a second functionality is attached (for example
carboxylic groups), it is advantageous for covalent conjugation
with targeting ligands and fluorescent molecules simultaneously.
Fluorescent iron oxide nanoparticles tagged with antibodies
for targeted imaging have been reported in recent years.37–42
Several of these adopted the polymer coating strategy. For
example, Yang et al.40 reported a magnetic-fluorescent nano-
hybrid with Cetuximab antibody for targeting human epithelial
cancer cells while Zou et al.41 demonstrated a system with PEG-
coated SPION with both 5-AM fluorescent label and
HuCC49DCH2 antibody for targeting colon cancer cells.
Another system reported by Makhluf et al.42 used PVA-coated
Fe3O4 nanoparticles with an anti-protein kinase C (PKC) alpha
antibody and a fluorescent tag for targeted imaging of sperm
cells. However, in these cases, the functionalities are grafted onto
the polymer shell which causes an increase in the overall size of
nanoparticles. A polymer-free, bifunctional magnetic nano-
particle system covalently tagged with fluorescent molecules and
antibodies is demonstrated here.
In this work, we use a simple direct-grafting synthetic pathway
for preparing Fe3O4 nanoparticles with both amine (NH2) and
carboxyl (COOH) functionalities co-existing in one nanoparticle.
The fluorescent molecules are covalently attached to the amine
groups while the carboxylic functional groups allow chemical
coupling with targeting ligands. This allows cancer-specific tar-
geting and has dual-imaging capability (fluorescent and MRI)
with low toxicity. The ability of these multifunctional nano-
particles (with an antibody specific for epithelia) to localize and
allow facilitated uptake into a pancreatic cancer cell line (Panc-1)
has been demonstrated in a controlled time-course study. WithThis journal is ª The Royal Society of Chemistry 2011the addition of distinct fluorophores and active targeting
elements this single nanoparticle platform would offer potential
for the progress of cancer diagnosis and treatment.Results and discussion
Formation of dual functional groups on the surface of Fe3O4
nanoparticles
Silanization with organofunctional alkoxysilane molecules was
used to functionalize the surface of 25 nm MNPs, following
a modified procedure described in the literature.36 The first step is
to prepare an amine-functionalized MNP (Fig. 1a), sample
denoted Fe3O4-NH2, by grafting APTES onto the surface of
commercial 25 nm Fe3O4 nanoparticles. The presence of amine
groups on Fe3O4-NH2 was qualitatively monitored by Fourier
transform infrared spectroscopy (FTIR). Fig. 2a indicates the
successful grafting of silane molecules evidenced by the presence
of the two broad bands at 3435 and 1600 cm1 in the FTIR
spectrum of Fe3O4-NH2, which were assigned to the N–H
stretching vibration and N–H bending respectively.43 The peaks
observed at 2925 and 2850 cm1 are due to the symmetric and the
asymmetric CH2 stretching modes respectively.
44 Fe–O–Si bonds
are masked in the FTIR spectrum by overlapping with the Fe–O
vibrations of magnetite at 580 cm1.45 On the other hand,
formation of the silane layer on the surface of nanoparticles was
confirmed by the band at 1118 cm1 corresponding to the Si–O–
Si bond.46
Quantitative analyses on the composition of the Fe3O4-NH2
nanoparticles were carried out using CHN elemental analysis
and thermogravimetric analysis (TGA), in order to estimate the
number of amine functional groups grafted on the surface. The
carbon content of carefully isolated functional nanoparticles
increased from 0.08% C in unfunctionalized nanoparticlesJ. Mater. Chem., 2011, 21, 12650–12659 | 12651
Fig. 2 FTIR spectra recorded between 4000 and 400 cm1 of function-
alized magnetic nanoparticles: Fe3O4-NH2 (a) shows the presence of the
NH2 groups by the bands at 3435 and 1600 cm
1; Fe3O4-NH2/COOH (b)
confirms the free carboxylic groups by the band at 1725 cm1.
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View Online(assigned to surface sorption of CO2) to 1.22% C in Fe3O4-NH2.
From the increased carbon content, there is an estimated
0.34 mmol of silane ligands per gram of nanoparticles and the
composition for Fe3O4-NH2 is (Fe3O4)13(O3SiC3H8N)1(H2O)1.
Based on the average diameter of a spherical particle being 25 nm
(from TEM analysis) and the density of Fe3O4 being 5.17 g cm
3,
an average number of 8600 amine molecules can be estimated on
top of each nanoparticle (or 4.38 silane ligands nm2, a distance
around 0.3 nm between two NH2 groups). This result is in
agreement with previous reports regarding the density of silane
ligands on nanoparticles.47,48 The results are summarized in
Table 1. The TGA thermogram of Fe3O4-NH2 in air (SI,
Figure S1†) shows two plateaus. The first between 30 and 150 C
was due to the evaporation of physically absorbed moisture on
the surface. This comprises 0.61% weight loss which is consistent
with the CHN water content of 0.56%. The second plateau
(between 150 and 600 C) corresponded to the decomposition of
propylamine groups. A similar temperature range was also
reported for aminosilane-coated cobalt ferrite nanoparticles.48
TGA was also used to estimate the number of silane ligands
anchored on the MNPs according to the following formula: N ¼
uNArV/MW, where N is the number of ligands on each nano-
particle, u is the mass loss in percent, NA is Avogadro’s number,
r is the density if the nanoparticle, V is the volume of one
nanoparticle and MW is the molar weight of the ligands. TheTable 1 Quantitative estimation of the number of amine, carboxylic and RI
analysis and the weight loss from TGA (air, 600 C)
Sample
CHN analysis
TGA
weight los
(C %) (%)
Fe3O4-NH2 1.22 2.03
Fe3O4-NH2/COOH 1.62 3.08
Fe3O4-NH-RITC/COOH 3.63 -
12652 | J. Mater. Chem., 2011, 21, 12650–12659weight loss of the Fe3O4-NH2 recorded by TGA is 2.03% between
150 and 600 C (SI, Figure S1†) which leads to approximately
8750 amine groups per nanoparticle. This number is consistent
with the number of groups based on the CHN data.
In the second synthetic step, carboxylic functional groups were
tethered by reacting the surface-bound amine groups with suc-
cinic anhydride, resulting in the sample denoted as Fe3O4-NH2/
COOH (Fig. 1b). The post-functionalization reaction for intro-
ducing free carboxylic groups was qualitatively monitored by
FTIR. Fig. 2b shows that the free carboxylic groups are present
as evidenced by the characteristic C]O stretching absorption at
1725 cm1 in the spectrum of Fe3O4-NH2/COOH.
44 Also the
frequencies in the region of 1640 cm1 and 1560 cm1 were
assigned to the C]O stretching band and N–H bending band in
the amide linkage, respectively.44 The size of MNPs before and
after the surface modification with amine and carboxyl groups
was examined using transmission electron microscopy (TEM)
and dynamic light scattering (DLS). The diameter of the
commercial Fe3O4 MNPs was found to be 25  5 nm from TEM
(Figure S2a†) while their average hydrodynamic size is 164 
6 nm from DLS (Figure S2c†). The chemical modification with
APTES and succinic anhydride did not change the particle size.
The size for Fe3O4-NH2/COOH is 24  4 nm from TEM
(Figure S2b†) and the average hydrodynamic diameter is 142 
8 nm (Figure S2d†). DLS size is larger since it measures the
hydrodynamic size of the core surrounded by the solvation
layers. Additionally DLS is more accurate for soft materials such
as polymers or proteins and the size of more dense materials may
be overestimated.49 The organic compositions of post-function-
alized Fe3O4-NH2/COOH nanoparticles were also quantified
using CHN elemental analysis and TGA. From the elemental
analysis, based on the carbon content increase (1.62% C in
Fe3O4-NH2/COOH), there is an estimated 0.09 mmoles of
carboxylic groups per gram of nanoparticles (corresponding to
approximately 2300 carboxylic acid groups per NP). The
composition for Fe3O4-NH2/COOH is (Fe3O4)13(O3-
SiC3H8N)0.75(O3SiC7H12NO3)0.25(H2O)1. The deconvolution of
the TGA data (SI, Figure S1) for Fe3O4-NH2/COOH (3.08%–
2.03%¼ 1.05% between 150 and 600 C) allows estimation of the
number of carboxylic acid groups as approximately 2300 per NP
(Table 1), which is consistent with the result from CHN
elemental analysis. These values correspond to only 25% of post-
functionalization but such incomplete conversion in the reaction
with succinic anhydride is likely to be due to steric hindrance,
heterogeneous phase conditions (solid/liquid) and protonation or
lack of nucleophilicity of some amine groups. Such partial
conversion of the amine groups to carboxylic acids offers the
bifunctionality on the surface of nanoparticles, with 75% free
amine groups and 25% carboxylic acid groups. The Fe3O4-NH2/TC groups per nanoparticle based on the carbon content from elemental
s
Number of
functional groups/NP
Number of
functional groups/NP
(CHN) (TGA)
8600 8750
2300 2300
2000 -
This journal is ª The Royal Society of Chemistry 2011
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View OnlineCOOH nanoparticles are advantageous for tagging two types of
functional species reacting with the two distinct –NH2 and
–COOH functionalities silane-bound to the NP surface (Fig. 1b).
Here we demonstrate this concept by using these groups to attach
two species, fluorescent molecules and specific proteins, on
a single particle through two different binding chemical strate-
gies. Amine groups were coupled with RITC (Fig. 1c) while
carboxyl groups were conjugated with proteins using the car-
bodiimide coupling (EDC, N-(3-Dimethylaminopropyl)-N0-
ethylcarbodiimide, was used as reagent). EDC was chosen
because unlike other cross-linking agents (such as glutaralde-
hyde) it does not become part of the final nanoparticle-bio-
molecule cross-link. Also, nanoparticle–nanoparticle and
protein–protein crosslinking are not avoidable using glutaral-
dehyde as a crosslinking reagent.
Rhodamine-tagged bifunctional Fe3O4 nanoparticles
Rhodamine B isothiocyanate (RITC) is a commonly used fluo-
rescent tag for biological samples which shows an orange-red
emission wavelength (lex ¼ 570 nm, lem ¼ 595 nm). Similar to
other isothiocyanate modified fluorophores, RITC is reactive
only towards the free amine groups (–NH2) present in the lysine
units of peptides and proteins. Since only mild reaction condi-
tions (room temperature, a buffer solution, pH ¼ 9.5) are
required for the binding of RITC with an amine group, the
Fe3O4-NH2/COOH nanoparticles are unlikely to be destabilized
and the carboxyl functionalities are to be preserved. In Fig. 3a
the fluorescent image of RITC-tagged nanoparticles, denoted as
Fe3O4-NH-RITC/COOH, is shown with clear red fluorescence,
which indicates the RITC molecules coupled to the nano-
particles. The amount of RITC bound to the nanoparticles can
also be quantified using CHN elemental analysis (Table 1). After
the RITC binding the carbon content increased from 1.62% to
3.63% which corresponds to approximately 2000 RITC mole-
cules per nanoparticle and is equivalent to approximately 30%
binding of the residual 75% free amine groups after carboxylic
acid functionalization. A 30% yield is reasonable considering
that the grafted –NH2 groups are rather close to each other (0.3
nm between groups) while the width of a rigid RITC molecule isFig. 3 Bright field and fluorescence microscopy images of (a) Fe3O4-
NH-RITC/COOH conjugated with FITC-BSA: the red fluorescence
shows that the RITC fluorescent dye is tagged to the nanoparticles and
the green fluorescence shows the FITC-BSA bound to the nanoparticles;
(b) Fe3O4-NH-RITC/COOH conjugated with FITC-IgG: red fluores-
cence shows that the RITC is tagged to the nanoparticles and the green
fluorescence shows that the FITC-IgG is also bound to the nanoparticles.
Scale bar: 25 mm.
This journal is ª The Royal Society of Chemistry 2011around 1.0 nm (measured with ChemBio3DUltra 12.0 software).
As shown in Figure S3,† the two neighboring –NH2 groups to the
RITC are likely to be blocked for further reactions. Also the
hydrodynamic size of the Fe3O4-NH-RITC/COOH was
measured to be 154  6 nm which is comparable with that of the
bifunctionalized nanoparticles and shows no evidence for large
aggregation (SI, Figure S2e†). The tagged RITC molecules have
two functions: first, their fluorescent property allows traceability
of the MNPs using fluorescence imaging; second, RITC mole-
cules can block the residual amine groups and prevent them from
reacting with the carboxyl groups in presence of the EDC
coupling reagent during protein/antibody coupling. This is
particularly important as the same chemistry is used for the
binding of proteins and antibodies onto the carboxyl-function-
alized Fe3O4 nanoparticles. Without the RITC units, cross-
linking of nanoparticles might occur, through the binding
between the two functionalities (–COOH and –NH2) on surface,
during antibody coupling.
In order to confirm that the carboxyl functional groups are still
chemically accessible on the Fe3O4-NH-RITC/COOH, a fluo-
rescent protein, bovine serum albumin tagged with fluorescein
isothiocyante or FITC-BSA (FITC lex¼ 488 nm, lem¼ 530 nm),
was used as a testing reagent. The fluorescent protein was
attached by conjugating the carboxyl groups of the nanoparticles
with the amine groups on the BSA surface using the EDC
coupling method. Since FITC-BSA shows green fluorescence,
Fe3O4-NH-RITC/COOH nanoparticles bound with this fluo-
rescent protein will show both red and green fluorescence. In
Fig. 3a the red and green fluorescence is observed on the nano-
particles depicted with a bright field image and this indicates that
the fluorescent protein has been successfully tagged onto the red-
fluorescent Fe3O4-NH-RITC/COOH nanoparticles, in turn
demonstrating the accessibility of the succinic anhydride-derived
carboxyl groups for bioconjugation.
Antibody-tagged Fe3O4 nanoparticles
In the next step, Fe3O4-NH-RITC/COOH nanoparticles were
decorated with a generic antibody molecule tagged with a green
fluorescent dye (FITC-IgG). FITC-IgG was chosen as a model
antibody because it is commercially available and the binding
chemistry for antibodies is applicable to all proteins.50 The active
carboxylic groups on Fe3O4-NH-RITC/COOH were covalently
conjugated with the amine groups on the antibody via the car-
bodiimide method.50 Fluorescence imaging was used to show
that the FITC-IgG molecules were attached to the Fe3O4-NH-
RITC/COOH nanoparticles (Fig. 3b).
The green and red fluorescence are observed on the nano-
particles, as shown in the bright field image. This indicates that
FITC-IgG was successfully bound to the red-fluorescent Fe3O4-
NH-RITC/COOH nanoparticles. As a result, specific antibodies
can be attached onto the Fe3O4-NH-RITC/COOH samples with
the same coupling protocol as for FITC-IgG or any other
proteins.
Evaluation of the effect of functionalized nanoparticles on the
magnetic resonance transverse relaxation rate
We assessed whether the functionalized nanoparticles are
behaving as contrast enhancers by measuring the transverseJ. Mater. Chem., 2011, 21, 12650–12659 | 12653
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View Onlinerelaxation time T2, on a 7 T MRI scanner. Measurements were
performed at room temperature for iron concentrations between
0.01 and 0.2 mM. Their efficiency as MRI contrast agents was
determined by calculation of the r2 relaxivities as the linear fit of
the inverse relaxation times as a function of iron concentration.
As seen on Fig. 4a, the signals intensity of T2 weighted images
changed with the increase in Fe concentration. Also, Fig. 4b
shows the relaxation rates 1/T2 against the different iron
concentrations. As expected, the relaxation rates vary linearly
with the iron concentration. The relaxivities (equivalent to the
slopes of the lines) were found to be 147.8, 149.9, 182.1 and
199 mM1s1 for Fe3O4, Fe3O4-NH2, Fe3O4-NH2/COOH and
Fe3O4-NH-RITC/COOH respectively. A direct comparison with
commercially available magnetic nanoparticles would not be
straightforward since the measurements would be performed
with different experimental parameters such as field strength.
However, our measurements show that the functionalized
nanoparticles could be employed as potential MRI contrast
agents and that the functionalization does not hinder the con-
trasting properties.
Cytotoxicity of functionalized Fe3O4 nanoparticles
In order to determine whether the Fe3O4-NH2/COOH nano-
particles can demonstrate potential for use in biological systemsFig. 4 (a) Moderately T2 weighted (TE/TR 11/5000 ms) MR images of
unfunctionalized Fe3O4; Fe3O4-NH2; Fe3O4-NH2/COOH and Fe3O4-
NH-RITC/COOH and (b) T2 relaxation rates plotted as function of Fe
concentration.
12654 | J. Mater. Chem., 2011, 21, 12650–12659(both in vitro and in vivo), their cytotoxicity in a human
pancreatic cancer cell line (Panc-1), which is also used for the
targeting experiments, was evaluated using the MTS cell prolif-
eration assay.51,52 This is a colorimetric assay which measures
a cells enzymatic ability to reduce 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS) to formazan dyes, giving rise to an orange colour; hence
greater absorbance equates to a greater estimation of cell
viability. Monolayers of Panc-1 pancreatic cancer cell lines were
grown and then loaded with increasing concentrations of
magnetic nanoparticles ranging from 25 to 200 mg mL1. Control
experiments consisting of untreated cells without addition of
nanoparticles were used for comparison. The results for
unfunctionalized Fe3O4 and Fe3O4-NH2/COOH nanoparticles
showed that the viability of cells was not affected by the presence
of the nanoparticles at a level # 125 mg mL1 after 48 h of
treatment; no statistical significance was observed (non-signifi-
cant [NS] p>0.05) (Fig. 5).
At concentrations of nanoparticles higher than 125 mg mL1
statistically significant decreases in absorbance were seen.
Although this was entirely compatible with a decrease in viability
of those cells, it cannot be excluded that this was due to cytostasis
of the cells caused by the engulfed particles as Fe3O4 nano-
particles are reported to be non-toxic for concentrations up to
250 mg mL1.53 However, more importantly is the finding that
Fe3O4-NH2/COOH nanoparticles did not cause any additional
toxic effect over and above that of Fe3O4. Other papers have also
reported that coated iron oxide nanoparticles have good
biocompatibility not only in vitro but also in vivo and that the
cytotoxicity effect is dependent on dose, compositions andFig. 5 Cytotoxicity of Panc-1 cells when incubated with different
concentrations of (a) unfunctionalized Fe3O4 and (b) Fe3O4-NH2/COOH
for 48 h. Statistical differences between control and samples are reported
as: *p<0.05, **p<0.0001 and NS (p>0.05) using the Mann-Whitney U
test. n ¼ 3 cultures.
This journal is ª The Royal Society of Chemistry 2011
Fig. 7 Fluorescence microscopy images showing the effect of EPCAM
modification on targeting abilities of nanoparticles (red fluorescence).
The cell nuclei were stained with DAPI (blue fluorescence). First panel:
Panc-1 incubated with Fe3O4-NH-RITC/CO-EPCAM for different
timelines (a) 1 h; (b) 6 h and (c) 24 h. Second panel: Panc-1 incubated with
Fe3O4-NH-RITC/CO-ISO for different timelines (d) 1 h; (e) 6 h and (f)
24 h. Third panel: Panc-1 incubated with Fe3O4-NH-RITC/COOH for
different timelines (g) 1 h; (h) 6 h and (i) 24 h. Scale bar 100 mm. Zoom-in
images of the highlighted regions (in rectangles) are shown in Figure 7.
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View Onlineparticle size.53–55 In addition to these findings, our study on
cytotoxicity of the bifunctionalized nanoparticles with Panc-1
cells also shows that the newly modified bi-functional surface
does not induce any toxicity. For the cell targeting experiments,
concentrations of 100 mg mL1 were used, and at this concen-
tration, our analysis showed that the nanoparticles are not
cytotoxic/cytostatic when compared with the controls.
Targeting pancreatic cancer cells
For targeting experiments the bifunctional surface of Fe3O4-NH-
RITC/COOH nanoparticles was exploited by adding an addi-
tional tag to focus the particle to the cell surface (in this case
Panc-1 human pancreatic cancer cell lines). An antibody to
a protein ubiquitously expressed on epithelial cell surfaces
(epithelial cell adhesion molecule, EPCAM) and known to be
highly expressed on Panc-1 cells56 (SI, Figure S4†) was chosen to
prove the principle of antibody-mediated localization of the
particles as pictured in Fig. 6.
These nanoparticles were denoted Fe3O4-NH-RITC/CO-
EPCAM. After conjugation, the content of immobilized
EPCAM was calculated to be 7.03 mg mg1 nanoparticles (SI,
Figure S5†) which correspond to approximately 1.35 molecules
EPCAM per MNP. To test the antibody-mediated localization
hypothesis, the Fe3O4-NH-RITC/CO-EPCAM nanoparticles
and two negative controls were used in these experiments:
Control 1: fluorescent-labelled nanoparticles tagged with a non-
specific isotype antibody (which has no specificity for the cells
receptors but with all the other characteristics of the antibodies
used in the experiment—a negative result would indicate that the
bound antibody per se has no role in targeting/uptake), named
Fe3O4-NH-RITC/CO-ISO and Control 2: Fe3O4-NH-RITC/
COOH antibody-free nanoparticles. These were chosen so as to
highlight the specificity of Fe3O4-NH-RITC/CO-EPCAM
nanoparticles, such that these particles should be preferentially
bound to Panc-1 cells, while Fe3O4-NH-RITC/CO-ISO and
Fe3O4-NH-RITC/COOH should not. Monolayers of Panc-1 cell
lines were separately incubated with these three nanoparticle
samples for 1, 6 and 24 h. The ability of the particles to localize
the cells was examined using fluorescence microscopy.
In Fig. 7a, in the first hour red fluorescence (from the bound
RITC) was only observed from the Panc-1 cells incubated withFig. 6 Schematic illustration of the concept of antibody targeting with
Panc-1 cancer cells. Fe3O4-NH-RITC/COOH nanoparticles were tagged
with specific EPCAM antibodies (nanoparticles denoted as Fe3O4-NH-
RITC/CO-EPCAM) or with non-specific isotype antibodies (nano-
particles denoted as Fe3O4-NH-RITC/CO-ISO).
This journal is ª The Royal Society of Chemistry 2011Fe3O4-NH-RITC/CO-EPCAM. Blue fluorescence is due to the
cell nuclei stained with 40,6-diamidino-2-phenylindole (DAPI)
for localization of the cells. This implies targeting of these
particles to Panc-1 cells, which has been mediated by surface-to-
surface antibody–antigen interactions. Red fluorescence was not
observed from the cells incubated with the two controls Fe3O4-
NH-RITC/CO-ISO or Fe3O4-NH-RITC/COOH nanoparticles
in the first hour (Fig. 7d and 7g). The addition of the non- specific
antibody (ISO) did not enhance the cellular uptake of nano-
particles due to the fact that this antibody does not present the
same specific antigen binding region as EPCAM. Therefore the
ISO antibody could not target the nanoparticles to the cell
surface, ruling out the non-specific interaction and uptake.
Fig. 8 shows more detailed cell images of Fig. 7 of the zoomed-
in areas. For cells incubated with Fe3O4-NH-RITC/CO-EPCAM
nanoparticles, some red fluorescence, likely to be aggregates of
Fe3O4-NH-RITC/CO-EPCAM nanoparticles, was observed
near the nuclei (stained with DAPI in blue) while some red
particles are localized on the cell membranes (indicated withJ. Mater. Chem., 2011, 21, 12650–12659 | 12655
Fig. 8 Magnified fluorescence images of insets in Fig. 6, showing the
effect of EPCAMmodification on targeting abilities of nanoparticles (red
fluorescence). The cell nuclei were stained with DAPI (blue fluorescence).
First panel: Panc-1 incubated with Fe3O4-NH-RITC/CO-EPCAM for
different timelines (a) 1 h; (b) 6 h and (c) 24 h. Second panel: Panc-1
incubated with Fe3O4-NH-RITC/CO-ISO for different timelines (d) 1 h;
(e) 6 h and (f) 24 h. Third panel: Panc-1 incubated with Fe3O4-NH-RITC/
COOH for different timelines (g) 1 h; (h) 6 h and (i) 24 h. Scale bar 25 mm.
Fig. 9 Confocal fluorescence and bright field microscopy images of
Panc-1 cells cultured with Fe3O4-NH-RITC/CO-EPCAM nanoparticles
for 1 h. (a) Middle section of the cells; (b) Magnified images of the inset
areas in (a). In blue the cell nuclei stained with DAPI and in red the
nanoparticles tagged with RITC.
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f L
iv
er
po
ol
 o
n 
16
 S
ep
te
m
be
r 2
01
1
Pu
bl
ish
ed
 o
n 
22
 Ju
ly
 2
01
1 
on
 h
ttp
://
pu
bs
.rs
c.
or
g 
| do
i:1
0.1
039
/C1
JM
113
70D
View Onlinewhite arrows in Fig. 8a). This suggested that the internalization
of Fe3O4-NH-RITC/CO-EPCAM nanoparticles occurs within
an hour. This was verified by examining sections of similarly
treated Panc-1 cells by confocal microscopy. Fig. 9a shows
middle section confocal images of Panc-1 with a zoom-in area
(Fig. 9b) to confirm that Fe3O4-NH-RITC/CO-EPCAM nano-
particles accumulated in the cells. It is proposed that these
nanoparticles were internalized via a receptor mediated endocy-
tosis facilitated by the successful binding onto the EPCAM
receptors on cell membranes.
Interestingly at 6 h Panc-1 cells incubated with the controls
also show some red fluorescence with intensity increasing at 24 h;
although this was substantially less intense than in the case of the
cells incubated with Fe3O4-NH-RITC/CO-EPCAM. Despite
some Fe3O4-NH-RITC/CO-EPCAM nanoparticles were still
found on the cell membranes, larger aggregates of red nano-
particles were observed next to the nuclei at 6 h (Fig. 8b). At 24 h,
there was no nanoparticle found on the cell membranes while
large aggregates of red nanoparticles were localized near the12656 | J. Mater. Chem., 2011, 21, 12650–12659nuclei. This suggested that all the nanoparticles bound to the
EPCAM receptors on the cell membranes were fully internalized
in 24 h.
This observation implied that the presence of the EPCAM
antibody on the nanoparticles successfully targeted the Panc-1
cells and facilitated their early uptake. For the controls experi-
ments, both Fe3O4-NH-RITC/CO-ISO and Fe3O4-NH-RITC/
COOH failed to attach to the cells in one hour (Fig. 8d and 8g).
However, by 6 h, there are some Fe3O4-NH-RITC/CO-ISO
nanoparticles (Fig. 8e) found on the cell membranes while a small
amount of Fe3O4-NH-RITC/COOH nanoparticles (Fig. 8h)
were aggregated near the nuclei. After 24 h, the cells started to
internalize nanoparticles regardless of their surface functionality
as all three nanoparticle samples were aggregated near the nuclei.
These control nanoparticles are thought to be internalized
through non-specific endocytosis processes.57
It is clear that the antibody-functionalized Fe3O4-NH-RITC/
CO-EPCAM particles have enhanced interaction with the Panc-
1 cells compared with the controls, leading to earlier and
increased levels of nanoparticle delivery to these cells. However it
is also evident, that nanoparticles, regardless of their surface
functionalization, will be internalized by the cells with time. On
the other hand, the targeting antibody offers both delivery of
larger amount of nanoparticle as well as a faster kinetic of
delivery (within 1 h instead of 6 h for controls) which may be
advantageous. Under natural conditions tumours would need
contact with chemotherapeutic agents for some time, either
continuously or as bolus injection before an effect is seen.
Although it is not shown here, a combination of multiple tar-
geting ligands or application of an external magnetic field used in
conjunction with the targeting antibody may accomplish the
panacea of tumour identification and destruction. The siloxaneThis journal is ª The Royal Society of Chemistry 2011
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View Onlinegrafting and subsequent chemistry used here allows the assembly
of a bifunctional surface of contrasting chemical properties on
a magnetic nanoparticle. This platform can be applied to the
synthesis of other multifunctional biosystems beyond biomedical
diagnosis.
Conclusions
A simple two-step covalent grafting process with functional
silanes on iron oxide nanoparticles leads to a bifunctional
surface. These nanoparticles possess both amine and carboxylic
acid functional groups, and are non-cytotoxic at a concentration
below 125 mg mL1. The combination of these groups enables the
covalent binding of two specific functionalities; fluorescent
molecules for imaging capability and antibodies for targeting
purpose. Fe3O4-NH-RITC/CO-EPCAMwas demonstrated to be
able to target epithelial specific EPCAM receptors on the Panc-1
pancreatic cancer cell lines in one hour and initiated a fast
internalization of nanoparticles. However, non-specific inter-
nalization was observed after 6 h but for a lower quantity of
nanoparticles. More importantly this robust, universal protocol
can be adapted for attaching other targeting ligands onto the
magnetic nanoparticles without a polymer shell, which will allow
targeting of other surface receptors that have a known marker. It
was shown that the fluorescence imaging and targeting capability
of these bifunctional nanoparticles can be further complimented
by the MRI contrasting property through the Fe3O4 core. As
expected the functionalized nanoparticles influence the signal
intensity on T2 weighted images as a function of iron concen-
tration. Multifunctional nanomaterials of this type are likely to
have advanced applications in cancer diagnosis due to their bi-/
multi-modular imaging capacity. In terms of therapeutic capa-
bility, this could be achieved by either attaching a third func-
tional group on surface for delivery of anti-cancer agents or by
magnetic hyperthermia exploiting the Fe3O4 cores.
58 Moreover,
this could also be aided by the possibility of dual magnetic/
antibody targeting for tumours. The potentials of these multi-
functional nanoparticles could give some much needed advan-
tages over conventional diagnostic methods and therapies for
cancers.
Experimental section
Materials
Iron (II, III) oxide nanoparticles (Nanopowder, 20–30 nm, 98%)
were purchased from Alfa Aesar. Succinic anhydride ($ 99%),
N,N-dimethylformamide anhydrous (DMF, 99.8%), dimethyl
sulfoxide (DMSO, $99.9%), tris(hydroxymethyl)aminomethane
(TRIS, $99.9%), rhodamine B isothiocyanate (RITC),
fluorescein 5(6)-isothiocyanate (FITC), N-(3-dimethylamino-
propyl)-N0-ethylcarbodiimide hydrochloride (EDC, $ 99%), N-
hydroxysulfosuccinimide (NHS, $ 98.5%), sodium bicarbonate
(NaHCO3, 99.5%), sodium carbonate (Na2CO3, $ 99.5%), 4
0,6-
diamidino-2-phenyindole (DAPI), phosphate buffer saline
tablets (PBS), bovine serum albumin (BSA), anti-rabbit IgG
(whole molecule)–FITC antibody produced in goat (FITC-IgG),
Bradford reagent and formalin solution neutral buffered (4%
PFA) were purchased from Sigma-Aldrich. 3-Amino-
propyltriethoxysilane (APTES, 98%) was acquired fromThis journal is ª The Royal Society of Chemistry 2011Fluorochem. All chemicals were used as received without any
further purification. Mouse IgG1 Monoclonal (NCG01) - Iso-
type Control antibody was purchased from Abcam Plc. Anti
Small Cell Carcinoma, epithelial antigen, cl.MOC-31 (EPCAM)
was obtained from Monosan. All aqueous solutions were
prepared using ultrapure water Milli-Q (Millipore, resistivity
18.2MU.cm @25 C). Bovine serum albumin tagged with FITC
was prepared according to literature procedures.59 Toluene was
dried using 4A molecular sieves (Sigma-Aldrich), activated at
300 C for 3 h.
Grafting of NH2 groups onto Fe3O4 nanoparticles
In a typical experiment, 500 mg of commercial Fe3O4 nano-
particles were dispersed in dry toluene (50 mL) using an ultra-
sonic bath (Fisher Scientific, FB15051, 30–40 kHz) for 10 min
under ambient conditions. Subsequently, APTES (0.5 mL,
2.1 mmol) was added dropwise to the nanoparticle suspension
and the reaction mixture was refluxed (110 C) overnight in air
using a mechanical stirrer. The nanoparticles were recovered
using a NdFeB permanent magnet (Magnet Sales, size: 10 mm
diameter and 5 mm height, strength1.18 T) and washed 5 times
with acetone to remove all traces of unreacted silanes. Finally,
the nanoparticles, denoted as Fe3O4-NH2, were dried under
vacuum for 16 h at room temperature.
Post-functionalization of Fe3O4–NH2 nanoparticles with
carboxylic acid groups
Fe3O4-NH2 nanoparticles (200 mg) were suspended in 45 mL of
anhydrous DMF under an N2 atmosphere. Then 30 mg
(0.3 mmol) succinic anhydride pre-dissolved in 5 mL anhydrous
DMF were added dropwise to the Fe3O4-NH2 suspension under
nitrogen. The resulting mixture was stirred for 24 h at room
temperature under nitrogen. The bifunctional Fe3O4-NH2/
COOH particles were separated from solution using a NdFeB
permanent magnet (same specifications as above) and then
washed 5 times with acetone in order to remove all traces of
DMF and unreacted succinic anhydride. The nanoparticles were
dried overnight under vacuum at room temperature.
Characterization of Fe3O4-NH2 and Fe3O4-NH2/COOH
nanoparticles
Fourier Transform Infrared Spectroscopy: FTIR spectra were
recorded on powder samples on a Bruker Tensor 27 Spectro-
meter. For each sample, 100 scans in the region from 400 to
4000 cm1 with a resolution of 4 cm1 were accumulated.
Thermal gravimetric analysis: TGA was carried out using a TA
instrument Q600 thermal balance. Typically 5–10 mg of nano-
particles were heated to 600 C with 10 C min1 in air and kept
isothermal at 600 C for 30 min to determine the amount of
organic content on the nanoparticles surface. CHN elemental
analysis (Thermo EA1112 Flash CHNS-O Analyzer) was also
used to analyze the organic content of the functionalized
samples. Fluorescent images were acquired using a Leica
DM2500 microscope equipped with a Leica DFC350 FX
Camera. Confocal microscopy images were obtained with
a Leica (SP2 AOBS) microscope. DLS measurements were per-
formed on a Zetasizer Nano ZS fromMalvern. MRI images wereJ. Mater. Chem., 2011, 21, 12650–12659 | 12657
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View Onlineacquired using a Bruker Avance III console and gradient system
interfaced to a Magnex Scientific 7T, horizontal bore magnet at
a 1H resonant frequency of 300 MHz. T2 was calculated from
a set of RARE60 images acquired with TR ¼ 5000 ms and TE
values of 11, 33, 55 and 77 ms.
Fluorescent dye and protein coupling on the bifunctionalized
nanoparticles
For fluorescence labelling, 1 mg Fe3O4-NH2/COOH nano-
particles were suspended in 0.9 mL 500 mM sodium carbonate
buffer at pH 9.5 and 0.1 mL of 0.01% w/v RITC in DMSO was
added to the suspension. The reaction mixture was covered with
aluminium foil to avoid any photobleaching during the binding
process and rotated in a Stuart Rotator SB2, at room tempera-
ture overnight. The fluorescently labelled nanoparticles were
separated using a permanent magnet and washed with 10 mM
Tris-HCl buffer at pH 8.2 until the solution ran clear. Subse-
quently, the washed nanoparticles were re-suspended in 0.5 mL
of 10 mM potassium phosphate buffer with 0.15 M of NaCl at
pH 5.5. The sample, denoted as Fe3O4-NH-RITC/COOH, was
stored at 4 C fully covered with aluminium foil.
For the binding of FITC-BSA onto the Fe3O4-NH-RITC/
COOH sample, 0.5 mL of activation solution (200 mMEDC and
50 mM NHS) was added to 1 mg of Fe3O4-NH-RITC/COOH
suspended in 0.5 mL potassium phosphate buffer pH 5.5 and the
mixture was rotated for 4 h at room temperature. The COOH
activated nanoparticles were washed with PBS buffer in order to
remove any residual EDC and NHS, and 10 mg FITC-BSA were
added to the suspension. The mixture is left to rotate overnight
covered with aluminium foil. The unbound FITC-BSA was
removed by washing 10 times with PBS buffer. The model anti-
body molecule (FITC-IgG) was coupled to the Fe3O4-NH-RITC/
COOH nanoparticles using the same protocol.
Cytotoxicity of functionalized nanoparticles
The human pancreatic cancer cell line, Panc-1, was obtained
from American Type Culture Collection and maintained in
DMEMmedium supplemented with 10% fetal calf serum, 2 mM
L-glutamine, 2500 I.U./mL penicillin and 5 mg mL1 streptomycin
(all from Sigma, Poole, UK) at 37 C in a humidified atmosphere
of 5% CO2. Cytotoxicity was assessed at 48 h using the EZ4U
non-radioactive cell proliferation assay (Biomedica, Vienna,
Austria) according to the manufacturer’s instructions. In brief,
cells were seeded in 96-well plates 5000 cells/well) in medium
(100 mL) and grown for 24 h. The medium was then replaced with
a fresh portion containing various concentrations of Fe3O4 and
Fe3O4-NH2/COOH (25–500 mg mL
1). Control wells containing
only fresh media were also included. Cells were incubated for
a further 48 h. Then, 10 mL of MTS reagent was added to each
well. Absorbance readings at 450 nm were taken at 3 h following
incubation with the MTS reagent. Experiments were performed
in triplicate using eight wells for each treatment.
Specific antibody tagging to Fe3O4-NH-RITC/COOH particles
For binding antibodies, 100 mg sterile Fe3O4-NH-RITC/COOH
were suspended in 0.5 mL of 10 mM potassium phosphate buffer
with 0.15 M of NaCl at pH 5.5. To this suspension 0.5 mL of12658 | J. Mater. Chem., 2011, 21, 12650–12659activation solution (200 mM EDC and 50 mM NHS) was added
and the suspension was rotated at room temperature for 4 h. The
COOH activated nanoparticles were washed with PBS buffer and
100 mL antibody (EPCAM or non-specific isotype antibody) was
added to them. The mixture was rotated overnight covered with
aluminium foil. The unconjugated antibodies were removed
during repeated washing steps with PBS buffer. The whole
binding procedure was carried out inside a class II flowhood.
Bradford assay was used to quantify the number of EPCAM
antibodies bound onto the nanoparticles. After binding, the
antibody concentration of the supernatant was determined as
15.97 mg mL1 using a calibration curve (see SI Figure S5†). This
suggests that 7.03 mgmL1 of EPCAMantibodies (or 32.07 1012
molecules) were bound onto the nanoparticles. Since, there are
23.7  1012 nanoparticles in 1 mg (calculated using the average
diameter of a nanoparticle as 25 nm and density of 5.17 g cm3 for
Fe3O4), it is equivalent to 1.35 EPCAM molecules per NP.
Antibody targeting experiments
Targeting experiments were conducted at 37 C in 5% CO2,
unless otherwise specified. To determine the targeting abilities
and the cellular uptake, 1  104 Panc-1 cells were seeded in
glassbase dishes (IWAKI 27mm) 24 h prior to the loading with
100 mg mL1 nanoparticles (Fe3O4-NH-RITC/CO-EPCAM,
Fe3O4-NH-RITC/CO-ISO and Fe3O4-NH-RITC/COOH) for 1,
6 and 24 h. After the set time interval, cells were then extensively
washed with PBS buffer and fixed with 4% paraformaldehyde
solution for 20 min. Fixed cells were washed 5 times with PBS
and cellular nuclei were stained with 0.5 mL of 2 mg mL1 40,6-
diamidino-2-phenyindole solution (DAPI).
Statistical analysis
Data were assumed to be non-parametric hence statistical
significance testing was performed using the Mann-Whitney U
test.61 A p value of less than 0.05 was considered to be significant.
Data were expressed in box and whisker plots and analyzed using
Stats Direct (version 2.6.2.).
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